SH PHARMA (02607) has released its financial report for the first quarter of 2026. The company reported operating revenue of 75.262 billion yuan, representing a year-on-year increase of 6.36%. Net profit attributable to equity shareholders of the listed company was 1.418 billion yuan, marking a 6.35% rise compared to the same period last year. Basic earnings per share for the quarter were 0.3823 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments